Effects of nicotine on depressive-like behavior and hippocampal volume of female WKY rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 1, 2010, Pages 62-69

  Tizabi, Yousef ^a   Hauser, Sheketha R ^a   Tyler, Khandra Y ^a   Getachew, Bruk ^a   Madani, Reza ^a   Sharma, Yukti ^a   Manaye, Kebreten F ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Depression; Forced swim test; Hippocampus; Nicotine; Stereology; WKY rats

Indexed keywords

NICOTINE TARTRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SIZE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; FEMALE; FORCED SWIMMING TEST; HIPPOCAMPUS; IMMOBILIZATION; LOCOMOTION; NONHUMAN; OPEN FIELD BEHAVIOR; RAT; WISTAR KYOTO RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DIAGNOSIS, COMPUTER-ASSISTED; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; EXPLORATORY BEHAVIOR; FEMALE; HIPPOCAMPUS; IMMOBILITY RESPONSE, TONIC; MOTOR ACTIVITY; NICOTINE; RATS; RATS, INBRED WKY; RATS, WISTAR; STEREOTAXIC TECHNIQUES; SWIMMING; TIME FACTORS;

EID: 73649114885     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.09.024     Document Type: Article

References (78)

1. aan het Rot M., Mathew S.J., and Charney D.S. Neurobiological mechanisms in major depressive disorder. CMAJ 180 (2009) 305-313
2. Andreasen J.T., and Redrobe J.P. Antidepressant-like effects of nicotine and mecamylamine in the mouse forced swim and tail suspension tests depend on strain and test, but not sex. Behav Pharm 20 (2009) 286-295
3. Andreasen J.T., Olsen G.M., Wiborg O., and Redrobe J.P. Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests. J Psychopharmacol 23 (2009) 797-804
4. Blalock J.A., Robinson J.D., Wetter D.W., Schreindorfer L.S., and Cinciripini P.M. Nicotine withdrawal in smokers with current depressive disorders undergoing intensive smoking cessation treatment. Psychol Addict Behav 22 (2008) 122-128
5. Buccafusco J.J., Beach J.W., and Terry Jr. A.V. Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther 328 (2009) 364-370
6. Buisson B., and Bertrand D. Nicotine addiction: the possible role of functional upregulation. Trends Pharmacol Sci 23 (2002) 130-136
7. Charney D.S. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 14 (1998) 11-14
8. Cook J.W., Spring B., and McChargue D. Influence of nicotine on positive affect in anhedonic smokers. Psychopharmacology 192 (2007) 87-95
9. Copeland R.L., Leggett Y.A., Kanaan Y.M., Taylor R.E., and Tizabi Y. Neuroprotective effects of nicotine against salsolinol-induced cytotoxicity: implications for Parkinson's disease. Neurotox Res 8 (2005) 289-293
10. Copeland R.L., Das J.R., Kanaan Y.M., Taylor R.E., and Tizabi Y. Antiapoptotic effects of nicotine in its protection against salsolinol-induced cytotoxicity. Neurotox Res 12 (2007) 61-69
11. Czéh B., and Lucassen P.J. What causes the hippocampal volume decrease in depression? Are neurogenesis glial changes and apoptosis implicated?. Psychiatry Clin Neurosci 257 (2007) 250-260
12. Das JR, Tizabi Y. Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotoxicity Res 2009;16:194-204.
13. De La Garza II R. Wistar Kyoto rats exhibit reduced sucrose pellet reinforcement behavior and intravenous nicotine self-administration. Pharmacol Biochem Behav 82 (2005) 330-337
14. Detke M.J., Rickels M., and Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121 (1995) 66-72
15. DiFranza J.R., and Wellman R.J. Sensitization to nicotine: how the animal literature might inform future human research. Nicotine Tob Res 9 (2007) 9-20
16. Djuric V.J., Dunn E., Overstreet D.H., Dragomir A., and Steiner M. Antidepressant effects of ingested nicotine in female rats of Flinders resistant and sensitive lines. Physiol Behav 67 (1999) 533-537
17. Ferguson S.M., Brodkin J.D., Lloyd G.K., and Menzaghi F. Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression. Psychopharmacology 152 (2000) 295-303
18. Fossati P., Radtchenko A., and Boyer P. Neuroplasticity: from MRI to depressive symptoms. Eur Neuropsychopharm 14 (2004) 503-510
19. Fowler C.D., Arends M.A., and Kenny P.J. Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice. Behav Pharmacol 19 (2008) 461-484
20. Fu Q., Heath A.C., Bucholz K.K., Lyons M.J., Tsuang M.T., True W.R., and Eisen S.A. Common genetic risk of major depression and nicotine dependence: the contribution of antisocial traits in a United States veteran male twin cohort. Twin Res Hum Genet 10 (2007) 470-478
21. Getachew B., Hauser S.R., Taylor R.E., and Tizabi Y. Desipramine blocks alcohol-induced anxiety- and depressive-like behaviors in two rat strains. Pharmacol Biochem Behav 91 (2008) 97-103
22. Glassman A.H. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 150 (1993) 546-553
23. Griebel G., Moreau J.L., Jenck F., Misslin R., and Martin J.R. Acute and chronic treatment with 5-HT uptake inhibitors differentially modulates emotional responses in anxiety models in rodents. Psychopharmacology 113 (1994) 463-470
24. Gunderson H.J., and Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J Microsc 147 (1987) 229-263
25. Gundersen H.J., Jensen E.B., Kieu K., and Nielsen J. The efficiency of systematic sampling in stereology. J Microsc 193 (1999) 199-211
26. Hayase T. Chronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: effects of anxiolytic and cannabinoid drugs. BMC Neurosci 8 (2007) 76-85
27. Hayase T. Nicotine (NC)-induced "depressive" behavioral symptoms and effects of antidepressants including cannabinoids. J Toxicol Sci 33 (2008) 555-564
28. Herzog C.J., Corbach B.C.S., Wuttke W., Schulte-Herbrüggen O., Hellweg R., Flügge G., and Fuchs E. Chronic social instability stress in female rats: a potential animal model for female depression. Neuroscience 159 (2009) 982-992
29. Hughes J.R. Effects of abstinence from tobacco: etiology, animal models, epidemiology, and significance: a subjective review. Nicotine Tob Res 9 (2007) 329-339
30. Keller J., Shen L., Gomez R.G., Garrett A., Solvason H.B., Reiss A., and Schatzberg A.F. Hippocampal and amygdalar volumes in psychotic and nonpsychotic unipolar depression. Am J Psychiatry 165 (2008) 872-880
31. Kendler K.S., Neal M.C., MacLean C.L., Heath A.C., Eaves L.J., and Kessler R.C. Smoking and major depressions: a causal analysis. Arch Gen Psychiatry 50 (1993) 36-43
32. Kessler R.C., McGonagle K.A., Swartz M., Blazer D.G., and Nelson C.B. Sex and depression in the National Comorbidity Survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord 29 (1993) 85-96
33. Lahmame A., del Arco C., Pazos A., Yritia M., and Amario A. Are Wistar-Kyoto rats a genetic model of depression resistant to antidepressants?. Eur J Pharmacol 337 (1997) 115-123
34. Leventhal A.M., Ramsey S.E., Brown R.A., LaChance H.R., and Kahler C.W. Dimensions of depressive symptoms and smoking cessation. Nicotine Tob Res 10 (2008) 507-517
35. Lopez-Rubalcaava C., and Lucki I. Strain differences in the behavioral effects of antidepressant drugs in the rat forced swimming test. Neuropsychopharm 22 (2000) 191-199
36. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8 (1997) 523-532
37. Lyons M., Hitsman B., Xian H., Panizzon M.S., Jerskey B.A., Santangelo S., Grant M.D., Rende R., Eisen S., Eaves L., and Tsuang M.T. A twin study of smoking, nicotine dependence, and major depression in men. Nicotine Tob Res 10 (2008) 97-108
38. Maeng S., and Zarate C.A. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry 9 (2007) 467-474
39. Manaye K.F., Paul W.C., O'Neil J.N., Huang S.Y., Tao X., De-Liang L., Tizabi Y., Ottinger M.A., Ingram D.K., and Mouton P.R. Neuropathological quantification of dtg APP/PS1: neuroimaging, stereology, and biochemistry. Age 29 (2007) 87-96
40. Manji H.K., Quiroz J.A., Sporn J., Payne J.L., Denicoff K.A., Gray N., Zarate C.A., and Charney D.S. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiat 15 (2003) 707-742
41. Mathew S.J., Manji H.K., and Charney D.S. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharm 33 (2008) 2080-2092
42. Matta S.G., Balfour D.J., Benowitz N.L., Boyd R.T., Buccafusco J.J., Caggiula A.R., Craig C.R., Collins A.C., Damaj M.I., Donny E.C., Gardiner P.S., Grady S.R., Heberlein U., Leonard S.S., Levin E.D., Lukas R.J., Markou A., Marks M.J., McCallum S.E., Parameswaran N., Perkins K.A., Picciotto M.R., Quik M., Rose J.E., Rothenfluh A., Schafer W.R., Stolerman I.P., Tyndale R.F., Wehner J.M., and Zirger J.M. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology 190 (2007) 269-319
43. McClernon F.J., Hiott F.B., Westman E.C., Rose J.E., and Levin E.D. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. Psychopharmacology 189 (2006) 125-133
44. McNally L., Bhagwagar Z., and Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 13 (2008) 501-510
45. Meagher D., and Murray D. Depression. Lancet 349 Suppl 1 (1997) sI17-sI20
46. Moreno-Coutiño A., Calderón-Ezquerro C., and Drucker-Colín R. Long-term changes in sleep and depressive symptoms of smokers in abstinence. Nicotine Tob Res 9 (2007) 389-396
47. Mouton P.R., Long J.M., Lei D.L., Howard V., Jucker M., Calhoun M.E., and Ingram D.K. Age and gender effects on microglia and astrocyte numbers in brains of mice. Brain Res 956 (2002) 30-35
48. Nutt D.J. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 69 (2008) 4-7
49. O'Neil J.N., Mouton P.R., Tizabi Y., Ottinger M.A., Lei D.L., Ingram D.K., and Manaye K.F. Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J Chem Neuroanat 34 (2007) 102-107
50. Overstreet D.H., Friedman E., Mathe A.A., and Yadid G. The Flinders Sensitive Line rat: a selectively bred putative animal model of depression. Neurosci Biobehav 29 (2005) 739-759
51. Paré W.P., and Redei E. Sex differences and stress response of WKY rats. Physiol Behav 54 (1993) 1179-1185
52. Picciotto M.R., and Zoli M. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front Biosci 13 (2008) 492-504
53. Picciotto M.R., Addy N.A., Mineur Y.S., and Brunzell D.H. It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol 84 (2008) 329-342
54. Porsolt R.D., Le P.M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
55. Quattrocki E., Baird A., and Yurgelun-Todd D. Biological aspects of the link between smoking and depression. Harv Rev Psychiatry 8 (2000) 99-110
56. Quik M., O'Leary K., and Tanner C.M. Nicotine and Parkinson's disease: implications for therapy. Mov Disord 23 (2008) 1641-1652
57. Rabenstein R.L., Caldarone B.J., and Picciotto M.R. The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology 189 (2006) 395-401
58. Rauhut A.S., Zentner I.J., Mardekian S.K., and Tanenbaum J.B. Wistar Kyoto and Wistar rats differ in the affective and locomotor effects of nicotine. Physiol Behav 93 (2008) 177-188
59. Semba J., Mataki C., Yamada S., Nankai M., and Toru M. Antidepressant-like effects of chronic nicotine on learned helplessness paradigms in rats. Biol Psychiatry 43 (1998) 389-391
60. Sheline Y.I., Gado M.H., and Kraemer H.C. Untreated depression and hippocampal volume loss. Am J Psychiat 160 (2003) 1516-1518
61. Soderpalm B. The SHR exhibits less "anxiety" but increased sensitivity to the anticonflict effect of clonidine compared to normotensive controls. Pharmacol Toxicol 65 (1989) 381-386
62. Son J.H., and Winzer-Serhan U.H. Chronic neonatal nicotine exposure increases mRNA expression of neurotrophic factors in the postnatal rat hippocampus. Brain Res 179 (2009) 159-165
63. Spring B., Cook J.W., Appelhans B., Maloney A., Richmond M., Vaughn J., Vanderveen J., and Hedeker D. Nicotine effects on affective response in depression-prone smokers. Psychopharmacology 196 (2008) 461-471
64. Stolerman I.P. Behavioural pharmacology of nicotine: implications for multiple brain nicotinic receptors. Ciba Found Symp 152 (1990) 3-16 discussion 16-22
65. Sziraki, Lipovac M.N., Hashim A., Sershen H., Allen D., Cooper T., Czobor P., and Lajtha A. Differences in nicotine-induced dopamine release and nicotine pharmacokinetics between Lewis and Fischer 344 rats. Neurochem Res 26 (2001) 609-617
66. Tejani-Butt S., Kluczynski J., and Paré W.P. Strain-dependent modification of behavior following antidepressant treatment. Prog Neuropsychopharm Biol Psychiat 27 (2003) 7-14
67. Thorndike A.N., Regan S., McKool K., Pasternak R.C., Swartz S., Torres-Finnerty N., and Rigotti N.A. Depressive symptoms and smoking cessation after hospitalization for cardiovascular disease. Arch Intern Med 168 (2008) 186-191
68. Tizabi Y. Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia. Neurotox Res 12 (2007) 233-246
69. Tizabi Y., Overstreet D.H., Rezvani A.H., Louis V.A., Clark E., Janowsky D.S., and Kling M.A. Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology 142 (1999) 193-199
70. Tizabi Y., Rezvani A.H., Russell L.T., Tyler K.Y., and Overstreet D.H. Depressive characteristics of FSL rats: involvement of central nicotinic receptors. Pharmacol Biochem Behav 66 (2000) 73-77
71. Tizabi Y., Al-Namaeh M., Manaye K.F., and Taylor R.E. Protective effects of nicotine on ethanol-induced toxicity in cultured cerebellar granule cells. Neurotox Res 5 (2003) 409-415
72. Tizabi Y., Manaye K.F., Smoot D.T., and Taylor R.E. Nicotine inhibits ethanol-induced toxicity in cultured cortical cells. Neurotox Res 6 (2004) 311-316
73. Tizabi Y., Manaye K.F., and Taylor R.E. Nicotine blocks ethanol-induced apoptosis in primary cultures of rat cerebral cortical and cerebellar granule cells. Neurotox Res 7 (2005) 319-322
74. Tizabi Y., Getachew B., Rezvani A.H., Hauser S.R., and Overstreet D.H. Antidepressant-like effects of nicotine and reduced nicotinic receptor binding in the Fawn-hooded rat, an animal model of co-morbid depression and alcoholism. Prog Neuropsychopharm Biol Psychiat 33 (2009) 398-402
75. Toborek M., Son K.W., Pudelko A., King-Pospisil K., Wylegala E., and Malecki A. ERK 1/2 signaling pathway is involved in nicotine-mediated neuroprotection in spinal cord neurons. J Cell Biochem 100 (2007) 279-292
76. Tyler K.Y., Edwards E., Copeland Jr. R.L., and Tizabi Y. Effects of nicotine in the congenital learned helplessness model of depression. Soc Neuroscience Abst 26 1 (2000) 1004
77. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 20 (1997) 92-98
78. Yu K.D., Liu Q., Wu J., and Lukas R.J. Kinetics of desensitization and recovery from desensitization for human alpha4beta2-nicotinic acetylcholine receptors stably expressed in SH-EP1 cells. Acta Pharmacol Sin 30 (2009) 805-817